NoAb BioDiscoveries, in collaboration with Sigma Advanced Genetic Engineering (SAGE) Labs, is introducing the use of SAGE knockout rats with its tools to investigate the blood-brain barrier including microdialysis and serial CSF collection, as a service to drug discovery researchers. Rats provided by SAGE Labs are available with knockouts of the specific drug transporter genes Mdr1a, Mrp1, Mrp2, Bcrp, or Oct1. These advanced animal models are designed to study and characterize the drug-like properties of compounds in vivo.
Dan Lichtman, President and CEO of NoAb BioDiscoveries, said “This partnership with SAGE Labs strengthens our service offering in drug discovery research. Preclinical researchers will benefit from the combined expertise and leadership of NoAb and SAGE.”
NoAb BioDiscoveries is a preclinical Contract Research Organization that offers a wide range ADME-PK Discovery services, specializing in in vivo models, in vitro assays and bioanalytical support. In addition to standard drug disposition studies, specific surgical catheterization points available at NoAb BioDiscoveries include jugular vein, carotid artery, hepatoportal vein, bile duct, and intestinal subsections. Such customized models form an important component of the tools that an investigator can use to address unique and specific questions about their compounds.
Date: July 1, 2012
Source: NoAb BioDiscoveries
Filed Under: Drug Discovery
